2018 hepatitis C Drug Development- Pipeline Analysis Report
With an estimated market value of over $20 billion by 2020, the Hepatitis C industry is considered as the rapidly growing healthcare markets. Hepatitis C affects around 200 million people worldwide and is associated with highest treatment failure rates. Currently, no vaccine is available against HCV. Due to the mutations in Hepatitis C virus, development of a prophylactic vaccine is highly challenging.
The condition is classified into 6 genotypes, of which GT-1 genotype is the most prevalent. The condition is a contagious liver disease which can be either acute or chronic. It can rapidly progress into serious liver problems including cirrhosis or liver cancer.
Over 100 companies and universities are focusing on developing treatment options for Hepatitis C (HCV).
To assist researchers and business development managers, VPA Research has come up with a comprehensive report on Hepatitis C (HCV) pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Hepatitis C (HCV) pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Hepatitis C (HCV) pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
The condition is classified into 6 genotypes, of which GT-1 genotype is the most prevalent. The condition is a contagious liver disease which can be either acute or chronic. It can rapidly progress into serious liver problems including cirrhosis or liver cancer.
Over 100 companies and universities are focusing on developing treatment options for Hepatitis C (HCV).
To assist researchers and business development managers, VPA Research has come up with a comprehensive report on Hepatitis C (HCV) pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Hepatitis C (HCV) pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Hepatitis C (HCV) pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of Figures
1.2 List of Tables
2 HEPATITIS C (HCV) PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Hepatitis C (HCV) Pipeline Snapshot
2.3 Hepatitis C (HCV) Pipeline by Phase
2.4 Hepatitis C (HCV) Pipeline by Company
2.5 Hepatitis C (HCV) Pipeline by Mechanism of Action
3 HEPATITIS C (HCV)- COMPANY WISE PIPELINE ANALYSIS
Achillion Pharmaceuticals
Adaptimmune
Akshaya Bio
Alios BioPharma
Alios BioPharma
Alla Chem
Amarillo Biosciences
Amarna Therapeutics BV
ARA Healthcare Pvt Ltd
Arbutus Biopharma
Array BioPharma
ARTES Biotechnology
Ascletis Inc
Atea Pharmaceuticals, Inc.
Beijing Kawin Technology Share-Holding
Beta Pharma
Biocad
Biotest Pharmaceuticals Corporation
Biotron Limited
Boehringer Ingelheim
Bolder Biotechnology
Bristol-Myers Squibb
Cenix BioScience
Cocrystal Discovery
Cocrystal Pharma Inc
Conatus Pharmaceuticals Inc
CytoPharm, Inc.
DEKK-TEC Inc
Dongguan HEC TaiGen Biopharmaceuticals
Eisai Co Ltd
F. Hoffmann-La Roche Ltd
Fides Pharma
FortuneRock(China)Co.,Ltd.
Galactica Biotech
GBF, Inc.
GeneOne Life Science, Inc.
Gilead Sciences
GinkgoPharma
GlaxoSmithKline
Hayashibara
HEC Pharm
Hemosol BioPharma
Idenix Pharmaceuticals
Idun Pharmaceuticals
ImmuneMed, Inc.
Immunocore
Inovio Pharmaceuticals
Integrated BioTherapeutics
InterMune Inc
iQur Ltd
Janssen Pharmaceuticals
Jenken Biosciences
JN-International Medical Corporation
Karyopharm Therapeutics
Kedrion SpA
Life Arc
Ligand Pharmaceuticals Inc
Medarex
Medivir AB
Merck & Co
Merck Sharp & Dohme Corp.
MetalloPharm
Microbio Co., Ltd.
Microbiotix
MultiCell Technologies Inc
Nabi Biopharmaceuticals
Nanogen Biopharmaceutical Co
Nitto BioPharma Inc
Novalex Therapeutics Inc
Novartis
NovaTarg Therapeutics
Nucorion Pharmaceuticals
Nuron Biotech
Okairos
Ono Pharmaceutical Co Ltd
Pharco Corporation
PharmaEssentia Corporation
Pomona Ricerca SR
Presidio Pharmaceuticals
PRISM Pharma
Quark Pharmaceuticals Inc
Regulus Therapeutics Inc
ReiThera Srl
Riboscience
Roche
Rodos BioTarget
Santaris Pharma
Savoy Pharmaceuticals
SomaGenics
Spring Bank Pharmaceuticals
TaiGen Biotechnology
TaiwanJ Pharmaceuticals
TGV-Laboratories
Therapure Biopharma
THEVAX
Tianjin SinoBiotech
Trek Therapeutics
Vakzine Projekt Management GmbH
WhanIn Pharmaceutical
XTL Biopharmaceuticals Ltd
4 HEPATITIS C (HCV) R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN HEPATITIS C (HCV) PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of Figures
1.2 List of Tables
2 HEPATITIS C (HCV) PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Hepatitis C (HCV) Pipeline Snapshot
2.3 Hepatitis C (HCV) Pipeline by Phase
2.4 Hepatitis C (HCV) Pipeline by Company
2.5 Hepatitis C (HCV) Pipeline by Mechanism of Action
3 HEPATITIS C (HCV)- COMPANY WISE PIPELINE ANALYSIS
Achillion Pharmaceuticals
Adaptimmune
Akshaya Bio
Alios BioPharma
Alios BioPharma
Alla Chem
Amarillo Biosciences
Amarna Therapeutics BV
ARA Healthcare Pvt Ltd
Arbutus Biopharma
Array BioPharma
ARTES Biotechnology
Ascletis Inc
Atea Pharmaceuticals, Inc.
Beijing Kawin Technology Share-Holding
Beta Pharma
Biocad
Biotest Pharmaceuticals Corporation
Biotron Limited
Boehringer Ingelheim
Bolder Biotechnology
Bristol-Myers Squibb
Cenix BioScience
Cocrystal Discovery
Cocrystal Pharma Inc
Conatus Pharmaceuticals Inc
CytoPharm, Inc.
DEKK-TEC Inc
Dongguan HEC TaiGen Biopharmaceuticals
Eisai Co Ltd
F. Hoffmann-La Roche Ltd
Fides Pharma
FortuneRock(China)Co.,Ltd.
Galactica Biotech
GBF, Inc.
GeneOne Life Science, Inc.
Gilead Sciences
GinkgoPharma
GlaxoSmithKline
Hayashibara
HEC Pharm
Hemosol BioPharma
Idenix Pharmaceuticals
Idun Pharmaceuticals
ImmuneMed, Inc.
Immunocore
Inovio Pharmaceuticals
Integrated BioTherapeutics
InterMune Inc
iQur Ltd
Janssen Pharmaceuticals
Jenken Biosciences
JN-International Medical Corporation
Karyopharm Therapeutics
Kedrion SpA
Life Arc
Ligand Pharmaceuticals Inc
Medarex
Medivir AB
Merck & Co
Merck Sharp & Dohme Corp.
MetalloPharm
Microbio Co., Ltd.
Microbiotix
MultiCell Technologies Inc
Nabi Biopharmaceuticals
Nanogen Biopharmaceutical Co
Nitto BioPharma Inc
Novalex Therapeutics Inc
Novartis
NovaTarg Therapeutics
Nucorion Pharmaceuticals
Nuron Biotech
Okairos
Ono Pharmaceutical Co Ltd
Pharco Corporation
PharmaEssentia Corporation
Pomona Ricerca SR
Presidio Pharmaceuticals
PRISM Pharma
Quark Pharmaceuticals Inc
Regulus Therapeutics Inc
ReiThera Srl
Riboscience
Roche
Rodos BioTarget
Santaris Pharma
Savoy Pharmaceuticals
SomaGenics
Spring Bank Pharmaceuticals
TaiGen Biotechnology
TaiwanJ Pharmaceuticals
TGV-Laboratories
Therapure Biopharma
THEVAX
Tianjin SinoBiotech
Trek Therapeutics
Vakzine Projekt Management GmbH
WhanIn Pharmaceutical
XTL Biopharmaceuticals Ltd
4 HEPATITIS C (HCV) R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN HEPATITIS C (HCV) PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Hepatitis C (HCV) Pipeline by Phase, H1- 2018
Figure 2: Hepatitis C (HCV) Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Hepatitis C (HCV) Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
Figure 1: Hepatitis C (HCV) Pipeline by Phase, H1- 2018
Figure 2: Hepatitis C (HCV) Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Hepatitis C (HCV) Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
LIST OF TABLES
Table 1: Hepatitis C (HCV) Pipeline by Phase, H1- 2018
Table 2: Hepatitis C (HCV) Pipeline by Companies, H1- 2018
Table 3: Hepatitis C (HCV) Pipeline by Mechanism of Action, H1- 2018
Table 4: Achillion Pharmaceuticals HCV Pipeline, May 2018
Table 5: Adaptimmune HCV Pipeline, May 2018
Table 6: Akshaya Bio HCV Pipeline, May 2018
Table 7: Alios BioPharma HCV Pipeline, May 2018
Table 8: Alios BioPharma HCV Pipeline, May 2018
Table 9: Alla Chem HCV Pipeline, May 2018
Table 10: Amarillo Biosciences HCV Pipeline, May 2018
Table 11: Amarna Therapeutics BV HCV Pipeline, May 2018
Table 12: ARA Healthcare Pvt Ltd HCV Pipeline, May 2018
Table 13: Arbutus Biopharma HCV Pipeline, May 2018
Table 14: Array BioPharma HCV Pipeline, May 2018
Table 15: ARTES Biotechnology HCV Pipeline, May 2018
Table 16: Ascletis Inc HCV Pipeline, May 2018
Table 17: Atea Pharmaceuticals, Inc. HCV Pipeline, May 2018
Table 18: Beijing Kawin Technology Share-Holding HCV Pipeline, May 2018
Table 19: Beta Pharma HCV Pipeline, May 2018
Table 20: Biocad HCV Pipeline, May 2018
Table 21: Biotest Pharmaceuticals Corporation HCV Pipeline, May 2018
Table 22: Biotron Limited HCV Pipeline, May 2018
Table 23: Boehringer Ingelheim HCV Pipeline, May 2018
Table 24: Bolder Biotechnology HCV Pipeline, May 2018
Table 25: Bristol-Myers Squibb HCV Pipeline, May 2018
Table 26: Cenix BioScience HCV Pipeline, May 2018
Table 27: Cocrystal Discovery HCV Pipeline, May 2018
Table 28: Cocrystal Pharma Inc HCV Pipeline, May 2018
Table 29: Conatus Pharmaceuticals Inc HCV Pipeline, May 2018
Table 30: CytoPharm, Inc. HCV Pipeline, May 2018
Table 31: DEKK-TEC Inc HCV Pipeline, May 2018
Table 32: Dongguan HEC TaiGen Biopharmaceuticals HCV Pipeline, May 2018
Table 33: Eisai Co Ltd HCV Pipeline, May 2018
Table 34: F. Hoffmann-La Roche Ltd HCV Pipeline, May 2018
Table 35: Fides Pharma HCV Pipeline, May 2018
Table 36: FortuneRock(China)Co.,Ltd. HCV Pipeline, May 2018
Table 37: Galactica Biotech HCV Pipeline, May 2018
Table 38: GBF, Inc. HCV Pipeline, May 2018
Table 39: GeneOne Life Science, Inc. HCV Pipeline, May 2018
Table 40: Gilead Sciences HCV Pipeline, May 2018
Table 41: GinkgoPharma HCV Pipeline, May 2018
Table 42: GlaxoSmithKline HCV Pipeline, May 2018
Table 43: Hayashibara HCV Pipeline, May 2018
Table 44: HEC Pharm HCV Pipeline, May 2018
Table 45: Hemosol BioPharma HCV Pipeline, May 2018
Table 46: Idenix Pharmaceuticals HCV Pipeline, May 2018
Table 47: Idun Pharmaceuticals HCV Pipeline, May 2018
Table 48: ImmuneMed, Inc. HCV Pipeline, May 2018
Table 49: Immunocore HCV Pipeline, May 2018
Table 50: Inovio Pharmaceuticals HCV Pipeline, May 2018
Table 51: Integrated BioTherapeutics HCV Pipeline, May 2018
Table 52: InterMune Inc HCV Pipeline, May 2018
Table 53: iQur Ltd HCV Pipeline, May 2018
Table 54: Janssen Pharmaceuticals HCV Pipeline, May 2018
Table 55: Jenken Biosciences HCV Pipeline, May 2018
Table 56: JN-International Medical Corporation HCV Pipeline, May 2018
Table 57: Karyopharm Therapeutics HCV Pipeline, May 2018
Table 58: Kedrion SpA HCV Pipeline, May 2018
Table 59: Life Arc HCV Pipeline, May 2018
Table 60: Ligand Pharmaceuticals Inc HCV Pipeline, May 2018
Table 61: Medarex HCV Pipeline, May 2018
Table 62: Medivir AB HCV Pipeline, May 2018
Table 63: Merck & Co HCV Pipeline, May 2018
Table 64: Merck Sharp & Dohme Corp. HCV Pipeline, May 2018
Table 65: MetalloPharm HCV Pipeline, May 2018
Table 66: Microbio Co., Ltd. HCV Pipeline, May 2018
Table 67: Microbiotix HCV Pipeline, May 2018
Table 68: MultiCell Technologies Inc HCV Pipeline, May 2018
Table 69: Nabi Biopharmaceuticals HCV Pipeline, May 2018
Table 70: Nanogen Biopharmaceutical Co HCV Pipeline, May 2018
Table 71: Nitto BioPharma Inc HCV Pipeline, May 2018
Table 72: Novalex Therapeutics Inc HCV Pipeline, May 2018
Table 73: Novartis HCV Pipeline, May 2018
Table 74: NovaTarg Therapeutics HCV Pipeline, May 2018
Table 75: Nucorion Pharmaceuticals HCV Pipeline, May 2018
Table 76: Nuron Biotech HCV Pipeline, May 2018
Table 77: Okairos HCV Pipeline, May 2018
Table 78: Ono Pharmaceutical Co Ltd HCV Pipeline, May 2018
Table 79: Pharco Corporation HCV Pipeline, May 2018
Table 80: PharmaEssentia Corporation HCV Pipeline, May 2018
Table 81: Pomona Ricerca SR HCV Pipeline, May 2018
Table 82: Presidio Pharmaceuticals HCV Pipeline, May 2018
Table 83: PRISM Pharma HCV Pipeline, May 2018
Table 84: Quark Pharmaceuticals Inc HCV Pipeline, May 2018
Table 85: Regulus Therapeutics Inc HCV Pipeline, May 2018
Table 86: ReiThera Srl HCV Pipeline, May 2018
Table 87: Riboscience HCV Pipeline, May 2018
Table 88: Roche HCV Pipeline, May 2018
Table 89: Rodos BioTarget HCV Pipeline, May 2018
Table 90: Santaris Pharma HCV Pipeline, May 2018
Table 91: Savoy Pharmaceuticals HCV Pipeline, May 2018
Table 92: SomaGenics HCV Pipeline, May 2018
Table 93: Spring Bank Pharmaceuticals HCV Pipeline, May 2018
Table 94: TaiGen Biotechnology HCV Pipeline, May 2018
Table 95: TaiwanJ Pharmaceuticals HCV Pipeline, May 2018
Table 96: TGV-Laboratories HCV Pipeline, May 2018
Table 97: Therapure Biopharma HCV Pipeline, May 2018
Table 98: THEVAX HCV Pipeline, May 2018
Table 99: Tianjin SinoBiotech HCV Pipeline, May 2018
Table 100: Trek Therapeutics HCV Pipeline, May 2018
Table 101: Vakzine Projekt Management GmbH HCV Pipeline, May 2018
Table 102: WhanIn Pharmaceutical HCV Pipeline, May 2018
Table 103: XTL Biopharmaceuticals Ltd HCV Pipeline, May 2018
Table 1: Hepatitis C (HCV) Pipeline by Phase, H1- 2018
Table 2: Hepatitis C (HCV) Pipeline by Companies, H1- 2018
Table 3: Hepatitis C (HCV) Pipeline by Mechanism of Action, H1- 2018
Table 4: Achillion Pharmaceuticals HCV Pipeline, May 2018
Table 5: Adaptimmune HCV Pipeline, May 2018
Table 6: Akshaya Bio HCV Pipeline, May 2018
Table 7: Alios BioPharma HCV Pipeline, May 2018
Table 8: Alios BioPharma HCV Pipeline, May 2018
Table 9: Alla Chem HCV Pipeline, May 2018
Table 10: Amarillo Biosciences HCV Pipeline, May 2018
Table 11: Amarna Therapeutics BV HCV Pipeline, May 2018
Table 12: ARA Healthcare Pvt Ltd HCV Pipeline, May 2018
Table 13: Arbutus Biopharma HCV Pipeline, May 2018
Table 14: Array BioPharma HCV Pipeline, May 2018
Table 15: ARTES Biotechnology HCV Pipeline, May 2018
Table 16: Ascletis Inc HCV Pipeline, May 2018
Table 17: Atea Pharmaceuticals, Inc. HCV Pipeline, May 2018
Table 18: Beijing Kawin Technology Share-Holding HCV Pipeline, May 2018
Table 19: Beta Pharma HCV Pipeline, May 2018
Table 20: Biocad HCV Pipeline, May 2018
Table 21: Biotest Pharmaceuticals Corporation HCV Pipeline, May 2018
Table 22: Biotron Limited HCV Pipeline, May 2018
Table 23: Boehringer Ingelheim HCV Pipeline, May 2018
Table 24: Bolder Biotechnology HCV Pipeline, May 2018
Table 25: Bristol-Myers Squibb HCV Pipeline, May 2018
Table 26: Cenix BioScience HCV Pipeline, May 2018
Table 27: Cocrystal Discovery HCV Pipeline, May 2018
Table 28: Cocrystal Pharma Inc HCV Pipeline, May 2018
Table 29: Conatus Pharmaceuticals Inc HCV Pipeline, May 2018
Table 30: CytoPharm, Inc. HCV Pipeline, May 2018
Table 31: DEKK-TEC Inc HCV Pipeline, May 2018
Table 32: Dongguan HEC TaiGen Biopharmaceuticals HCV Pipeline, May 2018
Table 33: Eisai Co Ltd HCV Pipeline, May 2018
Table 34: F. Hoffmann-La Roche Ltd HCV Pipeline, May 2018
Table 35: Fides Pharma HCV Pipeline, May 2018
Table 36: FortuneRock(China)Co.,Ltd. HCV Pipeline, May 2018
Table 37: Galactica Biotech HCV Pipeline, May 2018
Table 38: GBF, Inc. HCV Pipeline, May 2018
Table 39: GeneOne Life Science, Inc. HCV Pipeline, May 2018
Table 40: Gilead Sciences HCV Pipeline, May 2018
Table 41: GinkgoPharma HCV Pipeline, May 2018
Table 42: GlaxoSmithKline HCV Pipeline, May 2018
Table 43: Hayashibara HCV Pipeline, May 2018
Table 44: HEC Pharm HCV Pipeline, May 2018
Table 45: Hemosol BioPharma HCV Pipeline, May 2018
Table 46: Idenix Pharmaceuticals HCV Pipeline, May 2018
Table 47: Idun Pharmaceuticals HCV Pipeline, May 2018
Table 48: ImmuneMed, Inc. HCV Pipeline, May 2018
Table 49: Immunocore HCV Pipeline, May 2018
Table 50: Inovio Pharmaceuticals HCV Pipeline, May 2018
Table 51: Integrated BioTherapeutics HCV Pipeline, May 2018
Table 52: InterMune Inc HCV Pipeline, May 2018
Table 53: iQur Ltd HCV Pipeline, May 2018
Table 54: Janssen Pharmaceuticals HCV Pipeline, May 2018
Table 55: Jenken Biosciences HCV Pipeline, May 2018
Table 56: JN-International Medical Corporation HCV Pipeline, May 2018
Table 57: Karyopharm Therapeutics HCV Pipeline, May 2018
Table 58: Kedrion SpA HCV Pipeline, May 2018
Table 59: Life Arc HCV Pipeline, May 2018
Table 60: Ligand Pharmaceuticals Inc HCV Pipeline, May 2018
Table 61: Medarex HCV Pipeline, May 2018
Table 62: Medivir AB HCV Pipeline, May 2018
Table 63: Merck & Co HCV Pipeline, May 2018
Table 64: Merck Sharp & Dohme Corp. HCV Pipeline, May 2018
Table 65: MetalloPharm HCV Pipeline, May 2018
Table 66: Microbio Co., Ltd. HCV Pipeline, May 2018
Table 67: Microbiotix HCV Pipeline, May 2018
Table 68: MultiCell Technologies Inc HCV Pipeline, May 2018
Table 69: Nabi Biopharmaceuticals HCV Pipeline, May 2018
Table 70: Nanogen Biopharmaceutical Co HCV Pipeline, May 2018
Table 71: Nitto BioPharma Inc HCV Pipeline, May 2018
Table 72: Novalex Therapeutics Inc HCV Pipeline, May 2018
Table 73: Novartis HCV Pipeline, May 2018
Table 74: NovaTarg Therapeutics HCV Pipeline, May 2018
Table 75: Nucorion Pharmaceuticals HCV Pipeline, May 2018
Table 76: Nuron Biotech HCV Pipeline, May 2018
Table 77: Okairos HCV Pipeline, May 2018
Table 78: Ono Pharmaceutical Co Ltd HCV Pipeline, May 2018
Table 79: Pharco Corporation HCV Pipeline, May 2018
Table 80: PharmaEssentia Corporation HCV Pipeline, May 2018
Table 81: Pomona Ricerca SR HCV Pipeline, May 2018
Table 82: Presidio Pharmaceuticals HCV Pipeline, May 2018
Table 83: PRISM Pharma HCV Pipeline, May 2018
Table 84: Quark Pharmaceuticals Inc HCV Pipeline, May 2018
Table 85: Regulus Therapeutics Inc HCV Pipeline, May 2018
Table 86: ReiThera Srl HCV Pipeline, May 2018
Table 87: Riboscience HCV Pipeline, May 2018
Table 88: Roche HCV Pipeline, May 2018
Table 89: Rodos BioTarget HCV Pipeline, May 2018
Table 90: Santaris Pharma HCV Pipeline, May 2018
Table 91: Savoy Pharmaceuticals HCV Pipeline, May 2018
Table 92: SomaGenics HCV Pipeline, May 2018
Table 93: Spring Bank Pharmaceuticals HCV Pipeline, May 2018
Table 94: TaiGen Biotechnology HCV Pipeline, May 2018
Table 95: TaiwanJ Pharmaceuticals HCV Pipeline, May 2018
Table 96: TGV-Laboratories HCV Pipeline, May 2018
Table 97: Therapure Biopharma HCV Pipeline, May 2018
Table 98: THEVAX HCV Pipeline, May 2018
Table 99: Tianjin SinoBiotech HCV Pipeline, May 2018
Table 100: Trek Therapeutics HCV Pipeline, May 2018
Table 101: Vakzine Projekt Management GmbH HCV Pipeline, May 2018
Table 102: WhanIn Pharmaceutical HCV Pipeline, May 2018
Table 103: XTL Biopharmaceuticals Ltd HCV Pipeline, May 2018
